首页> 外文期刊>Molecular cancer research: MCR >PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors
【24h】

PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors

机译:PARP1捕获和DNA复制应激增强了与WEE1和PARP抑制剂组合的放射敏化

获取原文
获取原文并翻译 | 示例
           

摘要

KRAS mutations in non-small cell lung cancer (NSCLC) cause increased levels of DNA damage and replication stress, suggesting that inhibition of the DNA damage response (DDR) is a promising strategy for radiosensitization of NSCLC. This study investigates the ability of a WEE1 inhibitor (AZD1775) and a PARP inhibitor (olaparib) to radiosensitize KRAS-mutant NSCLC cells and tumors. In addition to inhibiting the DDR, these small-molecule inhibitors of WEE1 and PARP induce DNA replication stress via nucleotide exhaustion and PARP trapping, respectively. As monotherapy, AZD1775 or olaparib alone modestly radiosensitized a panel of KRAS-mutant NSCLC lines. The combination of agents, however, significantly increased radiosensitization. Furthermore, AZD1775-mediated radiosensitization was rescued by nucleotide repletion, suggesting a mechanism involving AZD1775-mediated replication stress. In contrast, radiosensitization by the combination of AZD1775 and olaparib was not rescued by nucleosides. Whereas both veliparib, a PARP inhibitor that does not efficiently trap PARP1 to chromatin, and PARP1 depletion radiosensitized NSCLC cells as effectively as olaparib, which does efficiently trap PARP, only olaparib potentiated AZD1775-mediated radiosensitization. Taken together, these mechanistic data demonstrate that although nucleotide depletion is sufficient for radiosensitization by WEE1 inhibition alone, and inhibition of PARP catalytic activity is sufficient for radiosensitization by olaparib alone, PARP1 trapping is required for enhanced radiosensitization by the combination of WEE1 and PARP inhibitors.
机译:非小细胞肺癌(NSCLC)中的KRAS突变导致DNA损伤和复制应激水平增加,表明DNA损伤反应(DDR)的抑制是NSCLC辐射敏化的有希望的策略。本研究研究了WEE1抑制剂(AZD1775)和PARP抑制剂(OLAPARIB)对KRAS-突变体NMSCLC细胞和肿瘤的能力的能力。除了抑制DDR之外,PEE1和PARP的这些小分子抑制剂分别通过核苷酸耗尽和PARP捕获诱导DNA复制应力。作为单药治疗,AZD1775或Olaparib单独均可放射敏感的KRAS-突变体NSCLC线。然而,药剂的组合显着增加了放射敏化症。此外,AZD1775介导的辐射敏化酶通过核苷酸恢复来拯救,旨在涉及AZD1775介导的复制应力的机制。相反,通过核苷的组合的组合的放射敏化未被核苷救出。虽然Veliparib,但PARP抑制剂,其不有效地将PARP1捕获到染色质,并且PARP1耗尽放射敏化的NSCLC细胞,如olAParib,它有效地捕获PARP,只有Olaparib调节AZD1775介导的放射敏化。总之,这些机制数据表明,尽管单独通过WEE1抑制抑制核苷酸耗尽足以进行放射胶囊化,但是对PARP催化活性的抑制是单独的奥拉帕里布的放射敏化,因此需要通过WEE1和PARP抑制剂的组合增强辐射敏化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号